IBP Stock Overview
Manufactures and sells various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Indo-Bangla Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳14.10 |
| 52 Week High | ৳21.40 |
| 52 Week Low | ৳12.80 |
| Beta | 0.19 |
| 11 Month Change | 4.44% |
| 3 Month Change | 7.63% |
| 1 Year Change | -17.06% |
| 33 Year Change | -34.29% |
| 5 Year Change | -32.72% |
| Change since IPO | -59.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBP | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -2.8% | -0.5% | -0.8% |
| 1Y | -17.1% | -17.7% | -19.9% |
Return vs Industry: IBP matched the BD Pharmaceuticals industry which returned -17.7% over the past year.
Return vs Market: IBP exceeded the BD Market which returned -19.9% over the past year.
Price Volatility
| IBP volatility | |
|---|---|
| IBP Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in BD Market | 7.6% |
| 10% least volatile stocks in BD Market | 3.6% |
Stable Share Price: IBP has not had significant price volatility in the past 3 months.
Volatility Over Time: IBP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BD stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 194 | A. F. M. Huq | www.indo-banglapharma.com |
Indo-Bangla Pharmaceuticals Limited manufactures and sells various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. Its principal products include analgesics and antipyretics, anthelmintic, anti-asthmatic, gastroprokinetic and antiemetic, antiprotozoal, non-hormone sex stimulant, non-steroidal, anti-inflammatory, steroids, and vitamins and minerals, as well as respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal categories. The company markets its products in various forms, such as tablets, capsules, intravenous fluids, liquids, suppositories, and injectables.
Indo-Bangla Pharmaceuticals Limited Fundamentals Summary
| IBP fundamental statistics | |
|---|---|
| Market cap | ৳1.64b |
| Earnings (TTM) | -৳18.08m |
| Revenue (TTM) | ৳211.61m |
7.7x
P/S Ratio-90.6x
P/E RatioIs IBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBP income statement (TTM) | |
|---|---|
| Revenue | ৳211.61m |
| Cost of Revenue | ৳182.04m |
| Gross Profit | ৳29.58m |
| Other Expenses | ৳47.66m |
| Earnings | -৳18.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 13.98% |
| Net Profit Margin | -8.55% |
| Debt/Equity Ratio | 2.2% |
How did IBP perform over the long term?
See historical performance and comparison